Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 9 of 9 results for fluticasone

  1. Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)

    Evidence-based recommendations on budesonide as an orodispersible tablet for inducing remission of eosinophilic oesophagitis in adults.

    Technology appraisal guidance
    Published
    23 June 2021
    View recommendations

    Sections for TA708

  2. Smartinhaler for asthma (MIB90)

    NICE has developed a medtech innovation briefing (MIB) on Smartinhaler for asthma .

    Medtech innovation briefing
    Published
    11 January 2017

  3. Sinusitis (acute): antimicrobial prescribing (NG79)

    This guideline sets out an antimicrobial prescribing strategy for acute sinusitis. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sinusitis is usually caused by a virus, lasts for about 2 to 3 weeks, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.

    Antimicrobial prescribing guideline
    Published
    27 October 2017
    View recommendations

    Sections for NG79

  4. PROPEL sinus implants for maintaining sinus patency after surgery (MIB253)

    NICE has developed a medtech innovation briefing (MIB) on PROPEL sinus implants for maintaining sinus patency after surgery .

    Medtech innovation briefing
    Published
    9 February 2021

  5. Chronic obstructive pulmonary disease: fluticasone furoate plus vilanterol (ESNM21)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    18 June 2013

  6. Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler (ESNM34)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Evidence summary
    Published
    3 March 2014

  7. Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) (ES18)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    14 June 2018

  8. NICE real-world evidence framework (ECD9)

    The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence

  9. Asthma: fluticasone/formoterol (Flutiform) combination inhaler (ESNM3)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Evidence summary
    Published
    12 October 2012